Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla Dubinsky

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
American Journal of Human Genetics|March 3, 2009
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn DiseaseKai Wang, Haitao Zhang, Subra Kugathasan, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel diseaseDanielle M M Harris, Arno R Bourgonje, Peder Rustøen Braadland, et al.
Gastroenterology|October 29, 2013
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's diseaseThomas D Walters, Mi-Ok Kim, Lee A Denson, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Cell|September 3, 2019
Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF TherapyJerome C Martin, Christie Chang, Gilles Boschetti, et al.
Human Molecular Genetics|February 24, 2010
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effectsKai Wang, Robert Baldassano, Haitao Zhang, et al.
Mucosal Immunology|December 14, 2018
Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosisYael Haberman, Melanie Schirmer, Phillip J Dexheimer, et al.
Gastroenterology|August 6, 2016
A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome CompositionDalin Li, Jean-Paul Achkar, Talin Haritunians, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2022
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel DiseasesLucas Guillo, Maria Abreu, Remo Panaccione, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
American Journal of Human Genetics|March 3, 2009
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn DiseaseKai Wang, Haitao Zhang, Subra Kugathasan, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel diseaseDanielle M M Harris, Arno R Bourgonje, Peder Rustøen Braadland, et al.
Gastroenterology|October 29, 2013
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's diseaseThomas D Walters, Mi-Ok Kim, Lee A Denson, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Cell|September 3, 2019
Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF TherapyJerome C Martin, Christie Chang, Gilles Boschetti, et al.
Human Molecular Genetics|February 24, 2010
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effectsKai Wang, Robert Baldassano, Haitao Zhang, et al.
Mucosal Immunology|December 14, 2018
Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosisYael Haberman, Melanie Schirmer, Phillip J Dexheimer, et al.
Gastroenterology|August 6, 2016
A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome CompositionDalin Li, Jean-Paul Achkar, Talin Haritunians, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2022
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel DiseasesLucas Guillo, Maria Abreu, Remo Panaccione, et al.
Pageof 16